GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today announced that the Company has re-scheduled its Annual Shareholders’ Meeting to December 16, 2008 in Munich. The meeting was previously scheduled for August 27, 2008. GPC Biotech’s management continues to be highly focused on rebuilding the Company and needs more time to appropriately prepare for the shareholders’ meeting.

About GPC Biotech

GPC Biotech AG is a publicly traded biopharmaceutical company focused on anticancer drugs. GPC Biotech's lead product candidate is satraplatin, an oral platinum compound. The Company has various anti-cancer programs in research and development that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) and has a wholly owned U.S. subsidiary in Princeton, New Jersey. For additional information, please visit GPC Biotech's Web site at www.gpc-biotech.com.

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of GPC Biotech. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. We direct you to GPC Biotech’s Annual Report on Form 20-F for the fiscal year ended December 31, 2007 and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of GPC Biotech. Forward-looking statements speak only as of the date on which they are made and GPC Biotech undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

GPC Biotech AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com
or
In the U.S.:
Laurie Doyle, +1 609-524-5884
Director, Investor Relations & Corporate Communications
usinvestors@gpc-biotech.com
or
Additional media contacts for Europe:
MC Services AG
Raimund Gabriel, +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu
or
Hilda Juhasz
hilda.juhasz@mc-services.eu
or
Additional investor contact for Europe:
Trout International LLC
Lauren Rigg, +44 207 936 9325
Vice President
lrigg@troutgroup.com